OK-432,立复欣,左氧氟沙星联用治疗耐多药肺结核近期疗效分析

目的　分析耐多药肺结核病人采用以 OK- 4 32 ,立复欣 ,左氧氟沙星为主的综合化疗方案治疗的近期疗效。　方法　对 2 0 0 1年 1月～ 2 0 0 2年 1月住院的 31例耐多药肺结核病人采用以 OK- 4 32 ,立复欣 ,左氧氟沙星为主、结合结核药敏试验加用其他敏感药物的化疗方案进行治疗。实施方案 :3DRSVAKVZE/ 6 DVZE+OK- 4 32。 3、6、9月末复查痰厚涂片找抗酸杆菌及胸片 ,每月复查肝肾功能及血常规 ,治疗前及疗程末分别检测 T细胞亚群。　结果　痰菌阴转情况 :3月末阴转 30例 (96 .7% ) ,6月末阴转 2 9例 (93.5 % ) ,疗程末 (9月末 )阴转 2 9例 (93.7% ) ;T细胞亚群检测 :CD4 / CD8治疗后明显高于治疗前 (P<0 .0 1) ;肝损害 1例 ,过敏性皮炎 1例 ,药物热 1例。　结论　该治疗方案近期疗效满意 ,药物副反应小 ,病人容易耐受 ,值得临床推广

The Short-term Therapeutic Effect Applying Sunthetic Regimen of OK-432.Rifamycin Sodium and Levefloxacin to MDR TB

Objective To explore the therapeutic effect of patients with multi-drug resistant pulmonary tuberculosis with synthetical therapeutic regimen(include ok-432?Rifamycin Sodium?levefloxacin). Methods 31 cases of multi-drug resistant pulmonary tuberculosis were treated with OK-432,Rifamycin Sodium,levofloxacin egimen, and combined with drug sensitivity test and add other sensitivey drugs from 2001,1-2002,1.the regimen is 3DRSAKVZE/6DVZE+OK- 432 (D: Pasiniazide, Rs: Rifamycin Sodium,V:levofloxacin, AK: Amikacin, Z: pyrazinamide, E: Ethambutol, OK-432: Salverine). Examine sputum smear and X-ray at 3,6,9 month, and examine liver` kidney function and blood routine very month. Detect T cell subgroup separatively before and at the end of the therapy. Result The sputum negative conversion rate was seperativelly 96.7%(30/31),93.7%(29/31),93.7%(29/31) in 3,6,9 month. T cell subgroup examination: CD4/CD8 have become distinctive better after therapy than before therapy. Complication: liver function damage 1 case, allergic dermatitis 1 case, drug fever 1 case. Conclusion The recent therapeutic effect of this regimen is satisfy and the side effect of drug is little, patients have good compliance.This regimen is worthy to be spreaded.